Business Context and Reporting Period
This Form 8-K is filed by OvaScience, Inc. (noting the metadata reference to Tempest Therapeutics appears to be an error as the filing explicitly names OvaScience) on October 29, 2018, with the earliest event reported on November 1, 2018. The filing details a Second Amendment to a Merger Agreement with Millendo Therapeutics, Inc., a planned post-closing financing, and a transfer of the company's stock listing from the Nasdaq Global Market to the Nasdaq Capital Market due to non-compliance with minimum bid price requirements.
Key Financial Metrics and Agreements
- Merger Valuation: Millendo Therapeutics' valuation is set at $155 million plus proceeds from pre-closing financing. OvaScience's valuation is lowered to $45.5 million, subject to adjustments.
- Pre-Closing Financing: Millendo's pre-closing financing, including convertible notes, must be consummated at a price per share of not less than $1.2096.
- Post-Closing Financing: OvaScience intends to complete a private placement of approximately $20 million of common stock with an institutional investor following the merger closing.
- Termination Fee: If the merger is terminated to accept a superior offer, the Post-Closing Financing Investor is entitled to a $1 million termination fee.
- Stock Price: The company's stock has traded below the $1.00 minimum bid price requirement for the Nasdaq Global Market.
Material Changes and Listing Status
On October 31, 2018, OvaScience's common stock listing was transferred from the Nasdaq Global Market to the Nasdaq Capital Market. This transfer was necessitated by the company's failure to maintain a minimum bid price of $1.00 per share over a 30-day period ending April 27, 2018. The company received an additional 180-day compliance period, extending until April 22, 2019, to regain compliance, potentially through a reverse stock split. The filing also notes adjustments to the merger agreement regarding the definition of outstanding shares, net cash adjustments for litigation, and lease obligations.
Outlook, Risks, and Contingencies
- Merger Completion: The company believes the proposed merger with Millendo will address the Nasdaq compliance issue. However, the transaction is subject to conditions including stockholder approval and regulatory filings.
- Delisting Risk: If the bid price does not close at or above $1.00 for 10 consecutive business days by April 22, 2019, the company expects to be delisted, at which point it may appeal to a Nasdaq hearing panel.
- Financing Conditions: The $20 million post-closing financing is contingent on the merger closing and the effectiveness of a Form S-3 resale registration statement. The investor has the right to terminate the agreement if the financing is not consummated by February 8, 2019.
- Forward-Looking Risks: Risks include failure to obtain stockholder approval, uncertainties in transaction timing, operating expense estimation errors, and potential adverse reactions to the transaction.
Investor Verification Checklist
- Verify the status of the Form S-3 resale registration statement required for the $20 million post-closing financing.
- Monitor the daily closing bid price of OvaScience stock to assess the likelihood of regaining Nasdaq compliance by April 22, 2019.
- Review the proxy statement, prospectus, and information statement filed on September 26, 2018, for details on the merger exchange ratio and voting requirements.
- Confirm the terms of the Second Amendment to the Merger Agreement regarding the $1.2096 minimum price for Millendo's pre-closing financing.
- Assess the potential impact of the $1 million termination fee obligation if the merger is terminated for a superior offer.